Investors of Capricor Therapeutics Urged to Join Legal Action for Stock Loss Recovery

Attention Capricor Therapeutics Investors

Shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) who incurred losses during the class period from October 9, 2024, to July 10, 2025, are being called upon to join a class action lawsuit. The Gross Law Firm has initiated this notice specifically targeting those who purchased shares of Capricor and are seeking recovery for their financial losses.

Background on the Allegations

The allegations stem from misleading statements made by the company's management regarding its lead drug candidate, deramiocel, which is aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Investors had been assured of the company’s capability of acquiring a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA). However, it is now alleged that while providing these positive reassurances, Capricor's management failed to disclose critical adverse facts about the drug's efficacy and safety data from the Phase 2 HOPE-2 trial.

On July 11, 2025, the situation took a significant turn when Capricor announced that it received a Complete Response Letter (CRL) from the FDA. This communication indicated that the application did not meet the necessary requirements for substantial evidence of effectiveness and highlighted the need for additional clinical data. Consequently, the aftermath of this announcement saw the price of Capricor stock plummet from $11.40 to $7.64 per share almost overnight, significantly impacting shareholders' investments.

Next Steps for Affected Shareholders

Shareholders are urged not to delay in registering for this class action. The deadline for joining as a lead plaintiff in the lawsuit is September 15, 2025. Interested investors can easily register by following the link: Registration Form. Joining the class action allows you to be kept in the loop via a portfolio monitoring service, offering updates on the case's progress.

Why Choose The Gross Law Firm?

The Gross Law Firm is well-regarded in the legal community, known for its focus on investor rights and class action cases. Their mission entails safeguarding those who have suffered due to deceptive practices in corporate setups. They prioritize investor recovery from losses that resulted from misleading statements and misinformation by companies. By joining this class action, shareholders will not incur upfront costs and can pursue the recovery of their losses as the case develops.

For any questions or further information, investors can contact The Gross Law Firm directly:

- Address: 15 West 38th Street, 12th floor, New York, NY, 10018
- Email: [email protected]
- Phone: (646) 453-8903.

In the wake of a challenging share price decline and allegations of corporate mismanagement, it is crucial for Capricor's investors to take action and ensure their rights are defended. By participating in this class action, shareholders have the potential to recover lost funds and hold the company accountable for its actions in this matter.

Join now and protect your investments!